NCT06421701招募中1 期
A Clinical Study of Anti-CD19 CAR-NK Cells in the Treatment of Refractory/Relapsed Systemic Lupus Erythematosus
Second Affiliated Hospital, School of Medicine, Zhejiang University1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- The proportion of subjects with adverse events
研究概览
简要总结
This study is a single-center, open-label, single-arm trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up;
- •Age range from 18 to 65 years old, regardless of gender;
- •Fulfilling the 2019 ACR/EULAR classification criteria of SLE;
- •Presence of anti-dsDNA or decreased C3/C4 levels;
- •SLEDAI-2K≥8；
- •Routine treatment is ineffective or the disease relapses after remission. Definition of routine treatment: use more than two drugs, including glucocorticoid (more than 1mg/kg/d), and any two or more of the following immunomodulatory drugs for more than 6 months: cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate, leflunomide, tacrolimus, ciclosporin, iguratimod, biological agents, including rituximab, belizumab, or telitacicept；
- •Hemoglobin ≥ 80g/L; white blood cell count ≥ 3 × 10^9/L；neutrophil count ≥ 1.5 × 10^9/L; platelets ≥ 30 × 10^9/L;
- •The functions of important organs are basically normal: ALT ≤ 2 × ULN; AST ≤ 2 × ULN; eGFR ≥ 30ml/min/1.73m2; total bilirubin ≤2.0 mg/dL; cardiac function: left ventricular ejection fraction (LVEF) ≥ 50%; non-oxygenated blood oxygen saturation >94%; prothrombin time (PT) ≤ 1.5 × ULN；international standardized ratio (INR) ≤ 1.5 × ULN；
- •Females of childbearing potential must use effective contraception during the study.
排除标准
- •History of severe allergy or known hypersensitivity to any of the active ingredients of the cell product；
- •Pregnant (or lactating) women;
- •Severe lupus nephritis (defined as serum creatinine > 2.5 mg/dL or 221 μmol/L), treatment with hemodialysis within 8 weeks prior to screening；
- •Other lupus crises, such as active central nervous system lupus, severe hemolytic anemia, severe thrombocytopenic purpura, severe agranulocytosis, severe myocardial damage, severe lupus pneumonia or pulmonary hemorrhage, severe lupus hepatitis, and severe vasculitis within 8 weeks prior to screening；
- •Combined with other autoimmune diseases requiring systemic therapy except for secondary sjogren's syndrome;
- •Clinically significant central nervous system diseases or pathological changes not caused by lupus prior to screening, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, convulsions, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis;
- •Abnormal test results for hepatitis B or C indicate the presence of an active or chronic infection, including positive HBsAg or positive HBcAb with HBV DNA levels exceeding the normal upper limit，positive hepatitis C antibody and detectable HCV RNA；positive serology for human immunodeficiency virus (HIV) or a known history of HIV infection; patients who test positive for HBsAg, have HBV DNA levels within the normal range, and are willing to reveive full-course antiviral therapy for hepatitis B are allowed to participate in this trial.
- •Cytomegalovirus DNA levels in the peripheral blood exceeding the normal upper limits；
- •Active or latent tuberculosis；
- •Presence of uncontrollable bacterial, fungal, viral or other infections, requiring antibiotic therapy;
- •Acquired and congenital immunodeficiency diseases；
- •IgA deficiency;
- •Other uncontrolled diseases: acute or chronic diseases that are clinically unstable or have not been effectively controlled and are not related to SLE；
- •History of malignant diseases such as malignant tumors, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, superficial bladder cancer, breast cancer;
- •Any active skin disease that may interfere with the study assessment of SLE, including but not limited to psoriasis, dermatomyositis, systemic sclerosis, non-LE cutaneous lupus manifestations (eg, cutaneous vascular disease, periungual telangiectasia, fingertip sclerosis, rheumatoid nodules, erythema multiforme, leg ulcers) or drug-induced lupus；
- •Prior treatment with cell therapy or any prior gene therapy product；
- •Contraindication to cyclophosphamide in combination with fludarabine;
- •Prior CD19-targeted therapy;
- •Received live vaccine treatment within 4 weeks prior to screening;
- •Subjects who have undergone major surgery within 8 weeks prior to screening, or who are scheduled to have surgery during the trial；
- •Have received B-cell targeted therapy within 4 weeks prior to screening;
- •Have received plasmapheresis within 3 months prior to screening;
- •Have participated in other clinical studies within 3 months prior to screening;
- •History of vital organ transplantation (eg, heart, lung, kidney, liver) or hematopoietic stem cell/or bone marrow transplantation；
- •Situations in which investigators consider it inappropriate to participate in the study.
研究组 & 干预措施
anti-CD19 CAR-NK cells
Experimental
To evaluate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus. All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by anti-CD19 CAR-NK cells infusion on Day 0, 3, and 6.
干预措施: anti-CD19 CAR-NK cells (Drug)
结局指标
主要结局
The proportion of subjects with adverse events
时间窗: 12 months
Incidence and severity of AEs and SAEs, including changes in laboratory values and vital signs as assessed by CTCAE v5.0.
次要结局
- Changes in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2000) score from baseline(Within 12 months after anti-CD19 CAR-NK cell infusion)
- Changes in the Physician Global Assessment (PGA) from baseline(Within 12 months after anti-CD19 CAR-NK cell infusion)
- Proportion of subjects with Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response(day 28, month 2, month 3, month 4, month 5, month 6, month 9 and month 12 after infusion.)
- Proportion of participants achieving definition of remission in SLE (DORIS) remission(day 28, month 2, month 3, month 4, month 5, month 6, month 9 and month 12 after infusion.)
- Proportion of participants achieving Lupus Low Disease Activity State (LLDAS)(day 28, month 2, month 3, month 4, month 5, month 6, month 9 and month 12 after infusion.)
- Change in proteinuria measured by 24h proteinuria or urine protein creatinine ratio (UPCR) from baseline(Within 12 months after anti-CD19 CAR-NK cell infusion)
- Changes in level of anti-nuclear antibody (ANA) in peripheral blood from baseline(Within 12 months after anti-CD19 CAR-NK cell infusion)
- Changes in levels of complement C3 and C4 in peripheral blood from baseline(Within 12 months after anti-CD19 CAR-NK cell infusion)
- CMAX of anti-CD19 CAR-NK cells(12 months)
- TMAX of anti-CD19 CAR-NK cells(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune DiseasesAntiphospholipid SyndromeSystemic Lupus ErythematosusSjogren's SyndromeNCT06614270Second Affiliated Hospital, School of Medicine, Zhejiang University15
Unknown
1 期
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell MalignanciesAcute Lymphocytic LeukemiaNon Hodgkin LymphomaChronic Lymphocytic LeukemiaNCT05410041Beijing Boren Hospital15
Unknown
1 期
Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell LymphomaRelapsed and Refractory B-cell LymphomaNCT05585996Second Affiliated Hospital, School of Medicine, Zhejiang University70
招募中
早期 1 期
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic MalignanciesChronic Lymphocytic LeukemiaB-cell LymphomaAcute Lymphoblastic LeukemiaNCT05739227Xuzhou Medical University12
已完成
1 期
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic LeukemiaRelapsed or Refractory Acute Lymphoblastic LeukemiaNCT04230473Juventas Cell Therapy Ltd.10